NCI Releases Annual Strategic Plan and Budget Proposal

NCI Releases Annual Strategic Plan and Budget Proposal

Every federal agency is required to submit a plan and proposal to Congress outlining its budget for the next fiscal year—or years—as well as justifications for how and why the department needs the requested allotment. In September 2018, the National Cancer Institute (NCI) released its Annual Plan and Budget Proposal for Fiscal Year 2020.

Institution Meets Magnet Designation by Incorporating ONS Standards in Care Delivery

Institution Meets Magnet Designation by Incorporating ONS Standards in Care Delivery

To meet or maintain Magnet designation, the American Nurses Credentialing Center (ANCC) Magnet Recognition Program expects organizations to incorporate specialty standards and guidelines into the care delivery system. 

Monitoring Surface Contamination of Hazardous Drugs and Considerations for Remediation

Monitoring Surface Contamination of Hazardous Drugs and Considerations for Remediation

Hazardous drugs are medications known to cause adverse health effects because of exposure in the workplace, according to the National Institute for Occupational Safety and Health. Examples of such agents include chemotherapy drugs, antivirals, hormones, and bioengineered drugs.

CMS Administrator Shares Three Points to Bolster Medicaid

CMS Administrator Shares Three Points to Bolster Medicaid

During a recent speech at the 2018 Medicaid Management Care Summit, Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma expressed a continued commitment to Medicaid’s legacy of supporting Americans in need.

Neuroendocrine Prostate Cancer Subtype Is Aggressive and More Common Than Expected

Neuroendocrine Prostate Cancer Subtype Is Aggressive and More Common Than Expected

Nearly 20% of men with metastatic, castration-resistant prostate cancer had tumors that developed into the treatment-emergent small-cell neuroendocrine (t-SCNC) subtype, which is associated with shorter survival than other subtypes, according to findings from a study published in the Journal of Clinical Oncology.

FDA Approves Talazoparib for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer

FDA Approves Talazoparib for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer

On October 16, 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib, a poly (ADP-ribose) polymerase inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2‑negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.

What APRNs Need to Know About Right to Try

What APRNs Need to Know About Right to Try

The Right-to-Try law, which has been in effect since May 2018, may have a misleading name, given that it doesn’t require drug manufacturers to grant access to experimental treatments that have passed phase I trials to any patient who seeks it. Rather, the law grants terminally ill patients the “right to ask” the drug company directly, but the request can be denied for several reasons (e.g., limited supply, expense).

The Overlooked Link Between Alcohol and Breast Cancer

The Overlooked Link Between Alcohol and Breast Cancer

At a recent college alumni dinner, a friend and wine expert pulled me aside and asked, “Is it true that wine increases the risk of breast cancer?” She knew I worked in the cancer division at the Centers for Disease Control and Prevention (CDC), so it was a reasonable question. I’ve been at wine tastings she’s hosted, and I needed to be straight. 

“Yes,” I said, “the evidence is clear: drinking alcohol of any kind increases breast cancer risk.”

Obamacare Premiums Drop; Short-Term Health Plans; Drug Pricing Gag Clause

Obamacare Premiums Drop; Short-Term Health Plans; Drug Pricing Gag Clause

Brazil’s Inaugural Oncology Nursing Conference Reminiscent of ONS’s Own Beginnings

Brazil’s Inaugural Oncology Nursing Conference Reminiscent of ONS’s Own Beginnings

What comes to mind when someone mentions Brazil? Do you think soccer? The 2016 Rio Olympics? Carnival? The Amazon rainforest? Although all of those are true, even more impressive is what’s happening in oncology nursing throughout Brazil. In August 2018, a small group of dedicated Brazilian oncology nurses—many of whom are ONS members—hosted the Inaugural Oncology Nursing Brazil 2018 conference in Sao Paulo.